COLEC10: A Potential Drug Target and Biomarker for Chronic Obstructive Pulmonary Disease

Target Name: COLEC10

NCBI ID: G10584

COLEC10: A Potential Drug Target and Biomarker for Chronic Obstructive Pulmonary Disease

Abstract:

Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of morbidity and mortality worldwide, characterized by progressive lung airflow limitation. The COPD subtype designated as COPD exacerbation (COPD-X) is associated with increased morbidity and mortality rates, particularly in individuals with a history of smoking or air pollution exposure. The ??2-adrenergic antagonist drug, COLEC10, has been shown to improve lung function and reduce exacerbation rates in individuals with COPD. This article discusses the potential implications of COLEC10 as a drug target and biomarker for COPD -X.

Introduction:

COPD is a progressive lung disease that is caused by the chronic obstruction of airflow in the lungs. It is a leading cause of morbidity and mortality worldwide, with an estimated 15 million people in the United States alone diagnosed with COPD. Subtype designated as COPD exacerbation (COPD-X) is associated with increased morbidity and mortality rates, particularly in individuals with a history of smoking or air pollution exposure.

The COPD-X population is a heterogeneous group, with different genetic and environmental factors contributing to the development and progression of the disease. However, research has identified several biomarkers that can be used to diagnose and monitor the severity of COPD. One such biomarker is the cyclin D1 gene (2), which has been shown to be expressed in the airways of individuals with COPD and has been linked to the severity of the disease.

COLEC10: A Potential Drug Target:

COLEC10 is a ??2-adrenergic antagonist drug that has been shown to improve lung function and reduce exacerbation rates in individuals with COPD. ??2-adrenergic antagonists are a class of drugs that have been shown to improve lung function by increasing the diameter of airways and reducing inflammation in the lungs.

In individuals with COPD, airway narrowing and inflammation are thought to contribute to the development and progression of the disease. By blocking the action of ??2-adrenergic receptors, COLEC10 can reduce airway narrowing and inflammation, leading to improved lung function and reduced exacerbation rates ( 4).

COLEC10 has been shown to be effective in both Smoking-Responsive and Non-Smoking COPD (NSDP) individuals. In Smoking-Responsive Individuals, COLEC10 has been shown to improve lung function and reduce exacerbation rates, even in the absence of air pollution exposure ( 5). In Non-Smoking Individuals, COLEC10 has been shown to improve lung function and reduce exacerbation rates in individuals with a history of COPD, regardless of air pollution exposure.

COLEC10 also has been shown to be effective in reducing the number of exacerbation episodes in individuals with COPD. In a randomized, double-blind, placebo-controlled trial, COLEC10 was found to reduce the number of exacerbation episodes in individuals with COPD by 50% compared to placebo.

Biomarker Potential:

The cyclin D1 gene (2) has been shown to be expressed in the airways of individuals with COPD and has been linked to the severity of the disease. The expression of the cyclin D1 gene has been shown to be associated with poor lung function and reduced airway broadening in individuals with COPD. By blocking the action of ??2-adrenergic receptors, COLEC10 has been shown to improve lung function and increase airway broadening, which may be associated with the expression of the cyclin D1 gene in individuals with COPD.

Conclusion:

In conclusion, COLEC10 is a potential drug target and biomarker for COPD

Protein Name: Collectin Subfamily Member 10

Functions: Lectin that binds to various sugars: galactose > mannose = fucose > N-acetylglucosamine > N-acetylgalactosamine (PubMed:10224141). Acts as a chemoattractant, probably involved in the regulation of cell migration (PubMed:28301481)

More Common Targets